Bedaquiline, Pretomanid, Linezolid, and Moxifloxacin: Mechanisms of Action, Drug Interactions, Adverse Effects and Use in Special Situations
Marcos Abdo Arbex · 2026
Read Bedaquiline, Pretomanid, Linezolid, and Moxifloxacin: Mechanisms of Action, Drug Interactions, Adverse Effects and Use in Special Situations by Marcos Abdo Arbex (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13210163.txt.
Description
Marcos Arbex reviews the four drug regimen for resistant tuberculosis in this 2026 paper. Tuberculosis still threatens world health. The World Health Organization's 2022 guidance made a six month, all oral course, shortened to BPaLM by its drug initials, the preferred treatment for rifampicin resistant disease.
Success with the short course hinges on handling drug interactions and side effects that can force changes mid course. The review walks through how each of the four drugs works, how the body absorbs and clears them, and their safety profiles. It then covers interactions with food and antacids, and gives guidance for pregnancy, breastfeeding, and liver or kidney impairment.
Catalog record
| CREATOR | Marcos Abdo Arbex |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 103 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |